McIlrath & Eck LLC Has $48,000 Stock Position in Celgene Co. (NASDAQ:CELG)

McIlrath & Eck LLC grew its stake in shares of Celgene Co. (NASDAQ:CELG) by 253.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 488 shares of the biopharmaceutical company’s stock after purchasing an additional 350 shares during the period. McIlrath & Eck LLC’s holdings in Celgene were worth $48,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC raised its holdings in shares of Celgene by 85.7% in the 2nd quarter. Renaissance Technologies LLC now owns 8,935,785 shares of the biopharmaceutical company’s stock worth $826,024,000 after acquiring an additional 4,122,685 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Celgene by 707.3% in the 2nd quarter. Nuveen Asset Management LLC now owns 4,476,814 shares of the biopharmaceutical company’s stock worth $413,836,000 after acquiring an additional 3,922,247 shares during the last quarter. York Capital Management Global Advisors LLC raised its holdings in shares of Celgene by 854.8% in the 2nd quarter. York Capital Management Global Advisors LLC now owns 2,588,825 shares of the biopharmaceutical company’s stock worth $239,311,000 after acquiring an additional 2,317,676 shares during the last quarter. TIG Advisors LLC raised its holdings in shares of Celgene by 77.3% in the 2nd quarter. TIG Advisors LLC now owns 3,583,622 shares of the biopharmaceutical company’s stock worth $331,270,000 after acquiring an additional 1,562,004 shares during the last quarter. Finally, Omni Partners LLP raised its holdings in shares of Celgene by 207.0% in the 2nd quarter. Omni Partners LLP now owns 1,842,219 shares of the biopharmaceutical company’s stock worth $170,295,000 after acquiring an additional 1,242,219 shares during the last quarter. Hedge funds and other institutional investors own 72.31% of the company’s stock.

CELG stock traded up $0.54 during trading on Friday, reaching $109.54. The stock had a trading volume of 5,706,800 shares, compared to its average volume of 6,764,924. The company’s 50 day moving average is $102.54 and its two-hundred day moving average is $96.76. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. The company has a market capitalization of $76.64 billion, a price-to-earnings ratio of 14.39, a P/E/G ratio of 0.51 and a beta of 1.41. Celgene Co. has a one year low of $58.59 and a one year high of $109.75.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.70 by $0.29. The firm had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter last year, the company posted $2.29 EPS. As a group, research analysts predict that Celgene Co. will post 10.7 earnings per share for the current fiscal year.

In other news, insider Terrie Curran sold 11,338 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the sale, the insider now owns 13,493 shares in the company, valued at approximately $1,325,957.11. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.39% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. Cowen restated a “hold” rating and issued a $102.00 target price on shares of Celgene in a report on Tuesday, July 30th. Standpoint Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a report on Friday, November 1st. BidaskClub upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Leerink Swann set a $115.00 price objective on shares of Celgene and gave the stock a “hold” rating in a research report on Friday, November 1st. Finally, Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and set a $101.00 price objective for the company. in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, nineteen have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Celgene has a consensus rating of “Hold” and an average target price of $97.31.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: Cost of equity and a company’s balance sheet

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit